GPM Reminds Investors of the August 30th Deadline in the Class Action Lawsuit Against Lipocine Inc. & Encourages Investors to...
August 17 2016 - 10:30AM
Business Wire
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the
August 30, 2016 deadline to file a lead plaintiff motion in
the class action filed on behalf of a class (the “Class”) of
investors who purchased Lipocine Inc. (“Lipocine” or the “Company”)
(NASDAQ: LPCN) securities between February 27, 2015 and June 28,
2016, inclusive (the “Class Period”).
Throughout the Class Period, Defendants made false and/or
misleading statements, as well as failed to disclose material
adverse facts about the Company’s business, operations, and
prospects. Specifically, Defendants made false and/or misleading
statements and/or failed to disclose: (1) that the Company
improperly designed and implemented its NDA for LPCN 1021; (2)
that, as a result, the FDA would deny or delay approval of the
Company’s lead product candidate; (3) that, as a result of the
foregoing, the Company’s future revenues and viability would be
jeopardized; and (4) that, as a result of the foregoing, the
Company’s financial statements, as well as Defendants’ statements
about Lipocine’s business, operations, and prospects, were false
and misleading and/or lacked a reasonable basis.
If you purchased Lipocine shares, you may move the Court no
later than August 30, 2016 to request appointment
as lead plaintiff. To be a member of the class you need not take
any action at this time; you may retain counsel of your choice or
take no action and remain an absent member of the Class. If you
wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests
with respect to these matters, please contact Casey Sadler,
Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by
email to shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160817005206/en/
Glancy Prongay & Murray LLP, Los AngelesCasey Sadler,
310-201-9150 or
888-773-9224shareholders@glancylaw.comwww.glancylaw.com
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Sep 2023 to Sep 2024